BR112018000209A2 - derivados de oxopiridina sibstituída - Google Patents

derivados de oxopiridina sibstituída

Info

Publication number
BR112018000209A2
BR112018000209A2 BR112018000209A BR112018000209A BR112018000209A2 BR 112018000209 A2 BR112018000209 A2 BR 112018000209A2 BR 112018000209 A BR112018000209 A BR 112018000209A BR 112018000209 A BR112018000209 A BR 112018000209A BR 112018000209 A2 BR112018000209 A2 BR 112018000209A2
Authority
BR
Brazil
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
oxopyridine
Prior art date
Application number
BR112018000209A
Other languages
English (en)
Other versions
BR112018000209B1 (pt
Inventor
Tersteegen Adrian
Hillisch Alexander
Meibom Daniel
Lang Dieter
Jimenez Nunez Eloisa
Stampfuss Jan
Ackerstaff Jens
Meier Katharina
Ellerbrock Pascal
Heitmeier Stefan
Röhrig Susanne
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of BR112018000209A2 publication Critical patent/BR112018000209A2/pt
Publication of BR112018000209B1 publication Critical patent/BR112018000209B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
BR112018000209-7A 2015-07-09 2016-07-05 Compostos derivados de oxopiridina substituída, processo para preparar o referido composto, uso do referido composto e medicamento compreendendo o mesmo BR112018000209B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP15176099.8 2015-07-09
EP16157350 2016-02-25
EP16157350.6 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives

Publications (2)

Publication Number Publication Date
BR112018000209A2 true BR112018000209A2 (pt) 2018-09-04
BR112018000209B1 BR112018000209B1 (pt) 2023-09-05

Family

ID=

Also Published As

Publication number Publication date
CY1123996T1 (el) 2022-07-22
JP2018519323A (ja) 2018-07-19
UY36780A (es) 2017-01-31
WO2017005725A1 (en) 2017-01-12
DK3319956T3 (da) 2021-03-29
TWI717367B (zh) 2021-02-01
CN113292539A (zh) 2021-08-24
EA201890111A1 (ru) 2018-06-29
EA036208B1 (ru) 2020-10-14
EP3319956B1 (en) 2021-01-06
NI201800001A (es) 2018-10-19
AU2016289746B2 (en) 2020-08-20
IL256556A (en) 2018-02-28
UA122341C2 (uk) 2020-10-26
HRP20210459T1 (hr) 2021-05-14
MA42376A (fr) 2018-05-16
DOP2018000004A (es) 2018-01-31
PE20180538A1 (es) 2018-03-20
CN108026072A (zh) 2018-05-11
CU24512B1 (es) 2021-05-12
US20180194745A1 (en) 2018-07-12
US10421742B2 (en) 2019-09-24
TW201706261A (zh) 2017-02-16
MY196640A (en) 2023-04-25
ES2856554T3 (es) 2021-09-27
LT3319956T (lt) 2021-02-10
JP6871180B2 (ja) 2021-05-12
PH12018500057A1 (en) 2018-07-09
AU2016289746A1 (en) 2018-01-25
GEP20197046B (en) 2019-12-10
RS61584B1 (sr) 2021-04-29
CO2018000113A2 (es) 2018-06-12
SI3319956T1 (sl) 2021-02-26
HUE053552T2 (hu) 2021-07-28
CL2018000039A1 (es) 2018-07-13
PL3319956T3 (pl) 2021-07-05
IL256556B (en) 2021-02-28
TN2018000011A1 (en) 2019-07-08
KR20180026761A (ko) 2018-03-13
MX2018000076A (es) 2018-02-26
KR102596164B1 (ko) 2023-11-01
ZA201800826B (en) 2021-08-25
CU20180001A7 (es) 2018-06-05
US20230024752A1 (en) 2023-01-26
JO3703B1 (ar) 2021-01-31
CN113292539B (zh) 2023-12-22
US11180471B2 (en) 2021-11-23
CA2990901A1 (en) 2017-01-12
CN108026072B (zh) 2021-08-17
MA42376B1 (fr) 2021-04-30
ECSP18001308A (es) 2018-03-31
CR20180017A (es) 2018-03-07
EP3319956A1 (en) 2018-05-16
HK1255045A1 (zh) 2019-08-02
SV2018005610A (es) 2018-04-27
US20190367478A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
DK3319956T3 (da) Substituerede oxopyridinderivater
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
DK3331528T3 (da) Muskarinagonister
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3360890T3 (da) Genterapi
DK3310450T3 (da) Olie-vand-separator
DK3331529T3 (da) Muskarinagonister
DK3270930T3 (da) Præeklampsi
DK3231803T3 (da) Dihydroindolizinonderivat
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3292136T3 (da) Penicillin-g-acylaser
DK3394281T3 (da) Gærcelle
ES2968023T3 (es) Derivados de oxoisoquinolina novedosos
DE112015006486A5 (de) Inkubationsrinne
DK3318308T3 (da) Badmintonketsjer
DK3274482T3 (da) Stenborsknop
DK3645513T3 (da) Benzazepinderivater
DE112016005599A5 (de) Strahlungsgrill
DE112015005898A5 (de) Gurtschlossbringer
ES1140083Y (es) Descompatactador tetrafunción
DE102015206660A8 (de) Plattenaufteilanlage
MA41641A (fr) Dérivés de tétrahydropyranylbenzamide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/07/2016, OBSERVADAS AS CONDICOES LEGAIS